Online inquiry

IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2891MR)

This product GTTS-WQ2891MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17RA gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001289905.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23765
UniProt ID Q96F46
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2891MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6373MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ4432MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ905MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ7561MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ10635MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ4398MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ15680MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ13887MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW